Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Arezzo – page 77

1 011 clinical trials in Arezzo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Arezzo at a glance
1 011
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 011 trials in Arezzo

Open in trial search

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development And Commercialization Inc.

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study on Anastrozole, Letrozole, Exemestane, and Tamoxifen for Women Aged 70+ with Early Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Anastrozole
  • Sponsor:University Of Florence

Bladder transitional cell carcinoma+2

Not recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Bronchiectasis+1

Not recruiting

Study on the Safety and Tolerance of BI 1291583 in Adults with Cystic Fibrosis Bronchiectasis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

B-cell type acute leukaemia

Not recruiting

Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hepatocellular carcinoma

Not recruiting

Study on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Tuberous sclerosis complex+2

Not recruiting

Study on Cannabidiol Oral Solution for Infants with Tuberous Sclerosis, Dravet Syndrome, or Lennox-Gastaut Syndrome Experiencing Uncontrolled Seizures

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Jazz Pharmaceuticals Research UK Limited

Malignant melanoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Hypertrophic cardiomyopathy

Not recruiting

Study Comparing Aficamten and Metoprolol for Adults with Symptomatic Hypertrophic Cardiomyopathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Arezzo

What the registry says about research in the country

01 Urological Oncology

Extensive research focusing on bladder cancer treatments, including innovative therapies combining immunotherapy with established treatments. Studies evaluate new approaches for both muscle-invasive and non-muscle invasive disease.

  • Bladder Cancer Immunotherapy
  • Urothelial Carcinoma Treatment
  • BCG Combination Therapies

Multiple trials exploring targeted treatments for patients with various stages of disease progression.

02 Prostate Cancer Research

Advanced studies examining new therapeutic approaches for metastatic prostate cancer, including novel drug combinations and targeted therapies for specific genetic mutations.

  • Castration-resistant Disease
  • Targeted Molecular Therapies
  • Hormone-based Treatments

Investigating innovative treatment sequences and combinations to improve patient outcomes.

03 Kidney Cancer Innovations

Cutting-edge research in renal cell carcinoma treatment, exploring immunotherapy combinations and targeted approaches for both early-stage and metastatic disease.

  • Immunotherapy Combinations
  • Targeted Molecular Agents
  • Advanced Disease Management

Focus on improving survival rates through novel therapeutic strategies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.